Prevalence and clinical features of thai patients with bullous pemphigoid

Asian Pacific Journal of Allergy and Immunology

Volumn 29, Issue 1, 2011, Pages 66-72

  Kulthanan, Kanokvalai ^a   Chularojanamontri, Leena ^a   Tuchinda, Papapit ^a   Sirikudta, Wararat ^a   Pinkaew, Samruay ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Bullous pemphigoid; Clinical course; Clinical features; Thai; Treatment

Indexed keywords

CYCLOPHOSPHAMIDE; DAPSONE; NICOTINAMIDE; PREDNISOLONE; TETRACYCLINE;

ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ARTICLE; BLADDER CANCER; BREAST CANCER; BULLOUS PEMPHIGOID; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; CORTICOSTEROID THERAPY; CUSHINGOID SYNDROME; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CONTROL; DRUG HYPERSENSITIVITY; EOSINOPHILIA; FEMALE; GROUPS BY AGE; HUMAN; IMMUNOFLUORESCENCE TEST; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; MUCOSAL DISEASE; ONSET AGE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PREVALENCE; RELAPSE; REMISSION; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; SEX RATIO; SKIN ULCER; SURVIVAL RATE; THAILAND; URTICARIA; UTERINE CERVIX CANCER;

AGED; AGED, 80 AND OVER; AUTOIMMUNE DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NERVOUS SYSTEM DISEASES; PEMPHIGOID, BULLOUS; PREDNISOLONE; PREVALENCE; SURVIVAL ANALYSIS; THAILAND; TREATMENT OUTCOME;

EID: 79958254527     PISSN: 0125877X     EISSN: 22288694     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Walsh SR, Hogg D, Mydlarski PR. Bullous pemphigoid: from bench to bedside. Drugs. 2005;65:905-26.
2. Wojnarowska F, Venning VA, Burge SM. Immunobullous diseases. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook's textbook of dermatology. 7 ed. Oxford: Blackwell science; 2004. p. 41.1-59.
3. Wong SN, Chua SH. Bullous pemphigoid seen at the National Skin Centre: a 2-year retrospective review. Ann Acad Med Singapore. 2002;31:170-4.
4. Chuang TY, Korkij W, Soltani K, Clayman J, Cook J. Increased frequency of diabetes mellitus in patients with bullous pemphigoid: a case-control study. J Am Acad Dermatol. 1984;11:1099-102.
5. Jedlickova H, Hlubinka M, Pavlik T, Semradova V, Budinska E, Vlasin Z. Bullous pemphigoid and internal diseases -A case-control study. Eur J Dermatol. 2010;20:96-101.
6. Rosina P, Chieregato C, D'Onghia FS. Bullous pemphigoid and diabetes mellitus. Acta Derm Venereol. 1996;76:497-8.
7. Ogawa H, Sakuma M, Morioka S, Kitamura K, Sasai Y, Imamura S, et al. The incidence of internal malignancies in pemphigus and bullous pemphigoid in Japan. J Dermatol Sci. 1995;9:136-41.
8. Wojnarowska F, Kirtschig G, Highet AS, Venning VA, Khumalo NP. Guidelines for the management of bullous pemphigoid. Br J Dermatol. 2002;147:214-21.
9. Joly P, Roujeau JC, Benichou J, Picard C, Dreno B, Delaporte E, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346:321-7.
10. Piamphongsant T. Dapsone for the treatment of bullous pemphigoid. Asian Pac J Allergy Immunol. 1983;1:19-21.
11. Murrell DF, Dick S, Ahmed AR, Amagai M, Barnadas MA, Borradori L, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol. 2008;58:1043-6.
12. Bernard P, Vaillant L, Labeille B, Bedane C, Arbeille B, Denoeux JP, et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. Arch Dermatol. 1995;131:48-52.
13. Bertram F, Brocker EB, Zillikens D, Schmidt E. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges. 2009;7:434-40.
14. Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJ, West J. Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study. BMJ. 2008;337:a180.
15. Adam BA. Bullous diseases in Malaysia: epidemiology and natural history. Int J Dermatol. 1992;31:42-5.
16. Baican A, Baican C, Chiriac G, Chiriac MT, Macovei V, Zillikens D, et al. Pemphigus vulgaris is the most common autoimmune bullous disease in Northwestern Romania. Int J Dermatol. 2010;49:768-74.
17. Nanda A, Al-Saeid K, Al-Sabah H, Dvorak R, Alsaleh QA. Clinicoepidemiological features and course of 43 cases of bullous pemphigoid in Kuwait. Clin Exp Dermatol. 2006;31:339-42.
18. Serwin AB, Bokiniec E, Piascik M, Masny D, Chodynicka B. Epidemiological and clinical analysis of pemphigoid patients in northeastern Poland in 2000-2005. Med Sci Monit. 2007;13:CR360-4.
19. Kyriakis KP, Paparizos VA, Panteleos DN, Tosca AD. Re-evaluation of the natural course of bullous pemphigoid. A prospective study. Int J Dermatol. 1999;38:909-13.
20. Cozzani E, Parodi A, Rebora A, Delmonte S, Barile M, Nigro A, et al. Bullous pemphigoid in Liguria: a 2-year survey. J Eur Acad Dermatol Venereol. 2001;15:317-9.
21. Gudi VS, White MI, Cruickshank N, Herriot R, Edwards SL, Nimmo F, et al. Annual incidence and mortality of bullous pemphigoid in the Grampian Region of North-east Scotland. Br J Dermatol. 2005;153:424-7.
22. Chang YT, Liu HN, Wong CK. Bullous pemphigoid--a report of 86 cases from Taiwan. Clin Exp Dermatol. 1996;21:20-2.
23. Bushkell LL, Jordon RE. Bullous pemphigoid: a cause of peripheral blood eosinophilia. J Am Acad Dermatol. 1983;8:648-51.
24. Durdu M, Baba M, Seckin D. The value of Tzanck smear test in diagnosis of erosive, vesicular, bullous, and pustular skin lesions. J Am Acad Dermatol. 2008;59:958-64.
25. Hadi SM, Barnetson RS, Gawkrodger DJ, Saxena U, Bird P, Merrett TG. Clinical, histological and immunological studies in 50 patients with bullous pemphigoid. Dermatologica. 1988;176:6-17.
26. Ahmed AR, Maize JC, Provost TT. Bullous pemphigoid. Clinical and immunologic follow-up after successful therapy. Arch Dermatol. 1977;113:1043-6.
27. Venencie PY, Rogers RS, 3rd, Schroeter AL. Bullous pemphigoid and malignancy: relationship to indirect immunofluorescent findings. Acta Derm Venereol. 1984;64:316-9.
28. Aekplakorn W. National health examination survey IV 2008-2009. Nonthaburi: The graphic system; 2010.
29. Taylor G, Venning V, Wojnarowska F, Welch K. Bullous pemphigoid and autoimmunity. J Am Acad Dermatol. 1993;29:181-4.
30. Taghipour K, Chi CC, Vincent A, Groves RW, Venning V, Wojnarowska F. The association of bullous pemphigoid with cerebrovascular disease and dementia: a case-control study. Arch Dermatol. 2010;146:1251-4.
31. Bastuji-Garin S, Joly P, Lemordant P, Sparsa A, Bedane C, Delaporte E, et al. Risk Factors for Bullous Pemphigoid in the Elderly: A Prospective Case-Control Study. J Invest Dermatol. 2010 Oct 14.
32. Bouscarat F, Chosidow O, Picard-Dahan C, Sakiz V, Crickx B, Prost C, et al. Treatment of bullous pemphigoid with dapsone: retrospective study of thirty-six cases. J Am Acad Dermatol. 1996;34:683-4.
33. Fivenson DP, Breneman DL, Rosen GB, Hersh CS, Cardone S, Mutasim D. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol. 1994;130:753-8.
34. Joly P, Benichou J, Lok C, Hellot MF, Saiag P, Tancrede-Bohin E, et al. Prediction of survival for patients with bullous pemphigoid: a prospective study. Arch Dermatol. 2005;141:691-8.
35. Parker SR, Dyson S, Brisman S, Pennie M, Swerlick RA, Khan R, et al. Mortality of bullous pemphigoid: an evaluation of 223 patients and comparison with the mortality in the general population in the United States. J Am Acad Dermatol. 2008;59:582-8.